ATAI Life Sciences NV (9VC) - Total Liabilities
Based on the latest financial reports, ATAI Life Sciences NV (9VC) has total liabilities worth €79.91 Million EUR (≈ $93.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ATAI Life Sciences NV - Total Liabilities Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's total liabilities have evolved over time, based on quarterly financial data. See ATAI Life Sciences NV (9VC) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
ATAI Life Sciences NV Competitors by Total Liabilities
The table below lists competitors of ATAI Life Sciences NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
Spain | €970.25 Million |
|
Advtech
JSE:ADH
|
South Africa | ZAC4.68 Billion |
|
Radiant Opto-Electronics Corp
TW:6176
|
Taiwan | NT$36.06 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩319.38 Billion |
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
Turkey | TL66.90 Billion |
|
Cosmax Inc
KO:192820
|
Korea | ₩1.55 Trillion |
|
SkiStar AB (publ)
ST:SKIS-B
|
Sweden | Skr5.60 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down ATAI Life Sciences NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ATAI Life Sciences NV.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ATAI Life Sciences NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ATAI Life Sciences NV (2019–2024)
The table below shows the annual total liabilities of ATAI Life Sciences NV from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €42.83 Million ≈ $50.08 Million |
-12.87% |
| 2023-12-31 | €49.16 Million ≈ $57.48 Million |
+23.91% |
| 2022-12-31 | €39.67 Million ≈ $46.38 Million |
+40.66% |
| 2021-12-31 | €28.21 Million ≈ $32.98 Million |
+74.33% |
| 2020-12-31 | €16.18 Million ≈ $18.92 Million |
+552.95% |
| 2019-12-31 | €2.48 Million ≈ $2.90 Million |
-- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more